Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.

In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.

Johnson & Johnson's Rybrevant and Lazcluze combination shows significant overall survival benefits over Tagrisso in the ...

Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.

Cagsy Parry, from Buckley, and Leon Hodgson, who lives near Loggerheads, are taking on the challenge after Cagsy's mum, Amanda, was told EGFR-positive lung cancer had spread to her brain in the form ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...